Core Viewpoint - The article highlights the significant transformation in the perception of China's biotech innovation capabilities by multinational pharmaceutical companies, particularly Roche, which has increased its investment and collaboration in the Chinese market [1][2]. Group 1: Investment and R&D Expansion - Roche has established a strong presence in China through its innovation center and accelerator, investing nearly 300 million RMB and facilitating numerous early-stage research collaborations [5][12]. - Shanghai has become a hub for multinational pharmaceutical companies, with six of the top ten global firms setting up R&D centers or incubators in the city, reflecting a shift towards open innovation and collaboration with local firms [3][6]. Group 2: Strategic Collaborations and Acquisitions - Recent high-profile licensing deals, such as the one between Shanghai-based Innovent Biologics and Pfizer, highlight the growing trend of multinational companies acquiring innovative drug pipelines from local firms, with upfront payments reaching record amounts [12][13]. - The article notes that the number of licensing transactions in China has surged, with the country accounting for 42% of global licensing deals with upfront payments exceeding $50 million in early 2025 [14][15]. Group 3: Innovation Ecosystem in Shanghai - Shanghai's biopharmaceutical industry has evolved significantly, with industrial output exceeding 200 billion RMB, supported by a robust ecosystem of research institutions, hospitals, and government policies promoting innovation [17][18]. - The city has established a comprehensive innovation ecosystem, enhancing the entire industry chain from R&D to clinical applications, which has attracted significant foreign investment and collaboration [19][20].

Group 1: Industry Overview - The innovation in China's pharmaceutical research and development has significantly increased, with the National Medical Products Administration approving 43 innovative drugs in the first half of 2025, a year-on-year growth of 59%, marking a historical high for the same period [1] - From 2018 to 2024, a total of 197 innovative drugs have been approved in China, with the annual approval rate rising from 11 in 2018 to 48 in 2024, indicating a steady growth trend [1] - Multiple supportive policies have contributed to the rapid development of innovative drugs in China, including the issuance of measures to support high-quality development of innovative drugs by the National Healthcare Security Administration and the National Health Commission [1] Group 2: Company Focus - Zhendong Pharmaceutical has made significant investments in innovative drug research and development, with R&D expenditure reaching 251 million yuan in 2024, a year-on-year increase of 25.27%, accounting for 8.44% of its operating revenue [2] - The company is focusing on innovative drug development in oncology and dermatology, with ongoing projects including ZD09 for gastric cancer, ZDH02 for breast cancer bone metastasis, and SH003 for atopic dermatitis [2] - Zhendong Pharmaceutical plans to leverage the capabilities of its newly established Shanghai New Drug Creation Center to accelerate breakthroughs in innovative drug development and enhance the quality of its product pipeline [2] Group 3: Future Outlook - The company aims to continue its transformation towards research and development innovation, aligning its existing product pipeline with advancements in collaboration with top domestic and international research institutions [3] - Zhendong Pharmaceutical is committed to injecting vitality into innovative drug research and development, ultimately providing more high-quality medications for global patients [3]

Group 1: Market Overview - The equity market continues to rise, with equity funds showing a net value increase of 3.06%, particularly in the healthcare theme funds which have demonstrated significant performance advantages [2] - Passive funds are seeing a shift, with inflows into financial real estate and dividend-themed ETFs, while large-cap broad-based ETFs are experiencing outflows [2] Group 2: Industry Research - The Yarlung Tsangpo River downstream hydropower project has officially commenced, with a total investment of approximately 1.2 trillion yuan and an installed capacity of 60-81 million kilowatts, benefiting the "duopoly" in hydropower equipment [4] - The project is expected to generate substantial construction and material orders, significantly boosting infrastructure investment growth in China [5] Group 3: Real Estate Market - As of July 20, 2025, new home transactions in 20 cities totaled 441,000 units, a decrease of 3.5%, while second-hand home transactions increased by 12.8% [6] Group 4: Steel Industry - The expectation for the exit of outdated production capacity has risen, with rebar prices reaching a new high since April 2025, indicating potential recovery in steel sector profitability [8] Group 5: Pharmaceutical Industry - The recent updates on the 2024 medical insurance fund and centralized procurement policies indicate a strong growth momentum for the innovative drug sector, with several companies successfully launching innovative drugs internationally [9] Group 6: Chemical Industry - The Ministry of Industry and Information Technology is set to introduce a stable growth plan for the petrochemical industry, which is expected to optimize the industry structure by phasing out outdated production capacity [10] Group 7: Machinery Industry - The engineering machinery sector is anticipated to benefit from the commencement of the Yarlung hydropower project, with domestic sales recovering and export volumes maintaining growth [10] Group 8: Company Research - The report on Mai Fushi indicates a strong market position due to its comprehensive product matrix and high customer retention, with projected revenues of 2.36 billion, 3.17 billion, and 4.13 billion yuan for 2025-2027 [11]

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [3][29]. Core Insights - The company is entering a concentrated output phase for innovative drug development, with a focus on high-value areas such as oncology, pain management, and autoimmune diseases. It has 20 ongoing first-class innovative drug projects, with 9 in clinical phase II and one product entering the registration application stage [1][2]. - The gradual advancement of innovative drugs is expected to reconstruct the company's valuation system, which currently relies heavily on traditional anesthetic products. The potential value of the innovative drug segment is not yet fully reflected in the company's valuation [2][19]. - The company has significantly increased its R&D investment, with expenditures rising from 404 million to 1.63 billion, and the number of R&D personnel growing from 671 to 2083 over the past decade [9][12]. Summary by Sections Financial Indicators - Projected revenue for 2023 is 24.525 billion, with a year-on-year growth rate of 9.8%. By 2027, revenue is expected to reach 32.346 billion [1]. - The net profit attributable to the parent company is projected to be 2.134 billion in 2023, with a significant increase to 2.913 billion by 2027 [1]. - The company's P/E ratio is expected to decrease from 16.9 in 2023 to 12.4 by 2027, indicating a potential increase in valuation as profits grow [1]. Innovative Drug Development - The company has established a multi-center R&D system in Wuhan and Yichang, enhancing its ability to transition from basic research to clinical application and commercialization [9][12]. - The innovative drug pipeline includes products targeting unmet medical needs in areas such as idiopathic pulmonary fibrosis and postoperative pain, with several products already in advanced clinical stages [13][15]. - Key products like the recombinant plasmid-hepatocyte growth factor injection and RFUS-144 are nearing commercialization, which is expected to significantly enhance market recognition and valuation [2][19]. Market Position and Future Outlook - The company is actively pursuing cutting-edge targets in drug development, with a clear differentiation strategy and ongoing investment in R&D [2][19]. - The innovative drug segment is anticipated to become a major growth driver for the company, contributing to a potential revaluation of its overall market position [19].

2025 年 7 月 21 日 行业研究 ——医药生物行业跨市场周报（20250720） 要点 行情回顾：上周， A 股医药生物指数上涨 4.00%，跑赢沪深 300 指数 2.91pp， 跑赢创业板综指 1.75pp，在 31 个子行业中排名第 2。港股恒生医疗健康指数上 涨 12.0%，跑赢恒生国企指数 8.56pp。 上市公司研发进度跟踪：上周，百奥泰的BAT5906注射液、恒瑞医药的 HRS-2162 注射液的临床申请新进承办。华东医药的 HDM1002、正大天晴的 bosakitug 正 在进行三期临床；联邦制药的 UBT251 正在进行二期临床；海思科的 HSK45030 正在进行一期临床。 本周观点：医保与集采支撑有力，创新药行业成长动能强劲 近日，国家公布了 2024 年医保基金的运行状况与集采政策最新动态。截至 2024 年底，全国基本医疗保险（含生育保险）基金总收入 34913.37 亿元，总支出 29764.03 亿元，全国基本医保统筹基金累计结存 38628.5 亿元。整体来看，医 保基金收支结构合理，体现出运行的稳健性。7 月 15 日，国家组织药品联合采 购办公室公布第十一批集采品 ...

Core Viewpoint - The announcement of positive top-line data from the Phase III clinical trial of ZORYVE cream (0.3% Roflumilast) for plaque psoriasis in China represents a significant breakthrough for East China Pharmaceutical and enhances its competitive edge in the field of autoimmune diseases and topical formulations [1][8]. Group 1: Product Efficacy and Safety - ZORYVE cream is the first approved topical PDE4 inhibitor for treating plaque psoriasis, demonstrating high efficacy and safety in clinical trials [2][3]. - The Phase III trial showed that 38.8% of patients in the treatment group achieved treatment success compared to 10.3% in the control group (P<0.0001) [3]. - Secondary endpoints also indicated significant improvements, with 43.6% of the treatment group achieving PASI-75 compared to 7.0% in the control group (P<0.0001) [3]. Group 2: Market Potential and Strategic Positioning - The autoimmune disease market is rapidly growing, with global drug market size projected to increase from $113.7 billion in 2018 to $176.7 billion by 2030 [5]. - East China Pharmaceutical has a comprehensive pipeline in the autoimmune sector, with over 20 products in development covering various indications [6]. - The company has established a "golden product combination" for psoriasis treatment, including monoclonal antibodies, oral small molecules, and topical formulations [6]. Group 3: Future Prospects and Collaborations - The collaboration with Arcutis for the development and commercialization of ZORYVE and ARQ-154 in Greater China and Southeast Asia is expected to provide new treatment options for patients [4][8]. - The company is actively pursuing innovative drug development and has built a robust platform for topical formulations, enhancing its market position in the autoimmune space [6][8]. - Upcoming approvals for other products, including biosimilars and innovative therapies, are anticipated to further strengthen the company's portfolio and market reach [7].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking the first coverage [2][10]. Core Insights - The report highlights the focus on innovative antibacterial treatments, particularly the commercialization of the core product, Contizole, and the ongoing development of its pipeline products [8][9][11]. - The company is positioned in the growing market of antibiotic resistance, with a strong emphasis on addressing clinical challenges through differentiated innovation [13][20]. Financial Forecast and Valuation - Projected revenues for the company from 2025 to 2027 are estimated at 1.74 billion, 2.05 billion, and 2.49 billion CNY respectively, reflecting a growth trajectory despite initial cash flow delays typical of biotech firms [10][46]. - The report utilizes a DCF valuation method, indicating that the current market valuation is relatively undervalued based on the company's growth potential and market position [10][21]. Business Overview - The company has established a solid domestic business foundation, with its core product, Contizole, showing significant sales growth of 88.3% in 2023 and projected continued growth of 43.51% in 2024 [4][27]. - The company has expanded its hospital coverage to 582 hospitals, with 150 hospitals formally approved for bulk procurement, enhancing market penetration [4][27]. Pipeline Development - The report details the ongoing global Phase III clinical trials for MRX-4, which is aimed at treating diabetic foot infections, and highlights the successful completion of Phase I trials for MRX-5 and MRX-8 [7][41][43]. - The company is actively pursuing international clinical development for its innovative products, with MRX-5 receiving FDA orphan drug designation, indicating strong potential for market entry [7][41][43]. Competitive Positioning - The company is strategically positioned in the antibacterial sector, focusing on multi-drug resistant bacteria, and has developed a comprehensive product matrix to address various infection types [20][21]. - The innovative approach includes a dual coverage strategy for Gram-positive and Gram-negative bacteria, enhancing its competitive edge in the market [9][20].

Core Viewpoint - Hunan Maijizhi Biotechnology Co., Ltd. (Maijizhi) has submitted an IPO application to the Hong Kong Stock Exchange, focusing on the development of innovative biopharmaceuticals for allergic and autoimmune diseases, with a strong pipeline of eight candidate products [1][3]. Company Overview - Maijizhi is a biopharmaceutical company in the clinical registration stage, established in 2016, with a focus on discovering, developing, and commercializing innovative biopharmaceuticals [1]. - The company has developed a robust pipeline consisting of eight innovative candidate products, including core products MG-K10, MG-014, and MG-013 [1][3]. Product Focus - The core product MG-K10 is a long-acting anti-IL-4Rα antibody, currently undergoing clinical trials for eight indications, including atopic dermatitis and asthma [3][7]. - MG-K10 is expected to redefine care standards due to its superior safety profile compared to existing therapies, with a lower incidence of adverse events [3][7]. - The product is the only long-acting anti-IL-4Rα candidate antibody verified through Phase III clinical research as of May 2025 [3]. Market Potential - The global market for allergic disease medications was valued at $61.8 billion in 2023 and is projected to grow to $122.2 billion by 2032, with a CAGR of 7.9% [4]. - In China, the market for allergic disease medications is expected to grow from $7.2 billion in 2023 to $31 billion by 2032, with a CAGR of 17.5% [4]. Competitive Landscape - MG-K10 directly competes with Sanofi/Regenron's Dupilumab, which achieved global sales of €11.7 billion in 2023, with a market size of nearly ¥2 billion in China [3][7]. - The treatment landscape for atopic dermatitis and asthma is currently limited, with only two approved treatments in China for atopic dermatitis and 46 biologics in clinical stages for asthma globally [6]. Financial Overview - Maijizhi's revenue for 2023 was ¥8.72 million, with projected revenues of ¥0 for 2024 and 2025, indicating reliance on third-party R&D service income [8][9]. - The company recorded net losses of ¥2.53 billion in 2023, ¥1.78 billion in 2024, and ¥270 million in the first quarter of 2025, highlighting the financial challenges faced during the R&D phase [8][9]. Commercialization Strategy - The company has signed an exclusive commercialization agreement with Kangzhe Pharmaceutical Group for MG-K10, allowing joint development in China and Singapore [8]. - The IPO proceeds will allocate ¥800 million for the industrialization of MG-K10 and ¥400 million for pipeline R&D [8]. Future Outlook - The NDA application for MG-K10 is expected to be submitted in late 2025, which will be crucial for overcoming commercialization challenges faced by domestic innovative drugs [10]. - The long-term commercial viability of MG-K10 will depend on expanding indications and market education efforts [10].

Group 1: Bid Medicine - Bid Medicine emphasizes capital operations and resource integration as key strategic focuses for future development, aiming to expand global business through various means and continuously seek acquisition opportunities [1] - The company has completed its global market layout, established multiple regional centers, and upgraded its U.S. warehouse and R&D center, resulting in rapid growth in overseas business [1] - Bid Medicine is facing a 20% fentanyl tax and a small 10% equivalent tariff on products sold in the U.S., but it has managed to pass on costs through price increases and discount adjustments, leading to minimal impact [1] - The company perceives a gradual recovery in industry demand, with improving orders from overseas and ongoing stimulation of market growth due to domestic innovative drug policies [1] Group 2: Medicy - Medicy is strengthening key technology research for hot drug development and building multiple innovative technology service platforms covering CGT, nucleic acid drugs, and PROTC [2] - The company has taken measures to ensure stable supply of experimental monkeys and has established a research laboratory in Boston, enhancing its overseas market expansion [2] - Medicy is focusing on talent development, optimizing internal organization and talent structure, and aims to improve operational conditions through cost reduction, efficiency enhancement, and strengthened R&D capabilities [2] - The domestic CRO industry is expected to benefit from policy support and the advancement of innovative drug development [2]

Investment Rating - The report maintains an investment rating of "Outperform" [6] Core Insights - The report highlights that Weili Zhibo is set to officially list on the Hong Kong Stock Exchange on July 25, 2025, with a pipeline of approximately 14 candidate drugs, 6 of which are in clinical development. The core product, the second-generation IO product PD-L1/4-1BB bispecific antibody LBL-024, is currently in a key registration clinical phase for treating lung neuroendocrine tumors [2][18] - The report notes that several PD-L1/4-1BB bispecific antibodies are under development globally, with Genmab's Acasunlimab leading in progress, having initiated a Phase III clinical trial for PD-L1 positive NSCLC in the second line. Weili Zhibo's LBL-024 is also in a critical registration clinical study for lung neuroendocrine tumors [21][22] - Early data from the PD-L1/4-1BB bispecific antibodies indicate that Weili Zhibo's LBL-024 has shown excellent overall response rate (ORR) data in first-line SCLC treatment, while Genmab's Acasunlimab has demonstrated superior survival data in second-line PD-L1 positive NSCLC [26] Summary by Sections Weekly New Drug Market Review - From July 14 to July 20, 2025, the top five companies in the new drug sector by stock price increase were Lepu Biotech (62.0%), Deqi Pharma (47.04%), Kaituo Pharma (41.99%), JAKS (41.95%), and Gilead Sciences (31.15%) [14][16] Weekly New Drug Industry Key Analysis - Weili Zhibo's innovative drug pipeline includes 14 candidate drugs, with 6 in clinical development. The focus is on the PD-L1/4-1BB bispecific antibody LBL-024, which is in a key registration clinical phase for lung neuroendocrine tumors [2][18] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were granted this week, but 6 new drug applications were accepted [3] Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 35 new drug clinical applications were approved, and 28 new drug clinical applications were accepted [4] Domestic Market Key Events TOP3 - Baiyue Shenzhou's application for the injection of Talazotuzumab for treating extensive-stage small cell lung cancer (ES-SCLC) has been accepted [5] Overseas Market Key Events TOP3 - Otsuka Pharmaceutical's APRIL antibody is expected to be included in priority review for treating adult primary immunoglobulin A nephropathy [10]